Prasugrel versus clopidogrel in patients with acute coronary syndromes

Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe, Gilles Montalescot, Witold Ruzyllo, Shmuel Gottlieb, Franz Joseph Neumann, Diego Ardissino, Stefano De Servi, Sabina A. Murphy, Jeffrey Riesmeyer, Govinda Weerakkody, C. Michael Gibson, Elliott M. Antman

Research output: Contribution to journalArticle

4534 Citations (Scopus)

Abstract

BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P

Original languageEnglish
Pages (from-to)2001-2015
Number of pages15
JournalNew England Journal of Medicine
Volume357
Issue number20
DOIs
Publication statusPublished - Nov 15 2007

Fingerprint

clopidogrel
Acute Coronary Syndrome
Percutaneous Coronary Intervention
Aspirin
Cause of Death
Stroke
Myocardial Infarction
Confidence Intervals
Hemorrhage
Safety
Prasugrel Hydrochloride
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., ... Antman, E. M. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357(20), 2001-2015. https://doi.org/10.1056/NEJMoa0706482

Prasugrel versus clopidogrel in patients with acute coronary syndromes. / Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antman, Elliott M.

In: New England Journal of Medicine, Vol. 357, No. 20, 15.11.2007, p. 2001-2015.

Research output: Contribution to journalArticle

Wiviott, SD, Braunwald, E, McCabe, CH, Montalescot, G, Ruzyllo, W, Gottlieb, S, Neumann, FJ, Ardissino, D, De Servi, S, Murphy, SA, Riesmeyer, J, Weerakkody, G, Gibson, CM & Antman, EM 2007, 'Prasugrel versus clopidogrel in patients with acute coronary syndromes', New England Journal of Medicine, vol. 357, no. 20, pp. 2001-2015. https://doi.org/10.1056/NEJMoa0706482
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine. 2007 Nov 15;357(20):2001-2015. https://doi.org/10.1056/NEJMoa0706482
Wiviott, Stephen D. ; Braunwald, Eugene ; McCabe, Carolyn H. ; Montalescot, Gilles ; Ruzyllo, Witold ; Gottlieb, Shmuel ; Neumann, Franz Joseph ; Ardissino, Diego ; De Servi, Stefano ; Murphy, Sabina A. ; Riesmeyer, Jeffrey ; Weerakkody, Govinda ; Gibson, C. Michael ; Antman, Elliott M. / Prasugrel versus clopidogrel in patients with acute coronary syndromes. In: New England Journal of Medicine. 2007 ; Vol. 357, No. 20. pp. 2001-2015.
@article{bde7e378330a4e4daf4c4e18f69aa9fd,
title = "Prasugrel versus clopidogrel in patients with acute coronary syndromes",
abstract = "BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1{\%} of patients receiving clopidogrel and 9.9{\%} of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95{\%} confidence interval [CI], 0.73 to 0.90; P",
author = "Wiviott, {Stephen D.} and Eugene Braunwald and McCabe, {Carolyn H.} and Gilles Montalescot and Witold Ruzyllo and Shmuel Gottlieb and Neumann, {Franz Joseph} and Diego Ardissino and {De Servi}, Stefano and Murphy, {Sabina A.} and Jeffrey Riesmeyer and Govinda Weerakkody and Gibson, {C. Michael} and Antman, {Elliott M.}",
year = "2007",
month = "11",
day = "15",
doi = "10.1056/NEJMoa0706482",
language = "English",
volume = "357",
pages = "2001--2015",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "20",

}

TY - JOUR

T1 - Prasugrel versus clopidogrel in patients with acute coronary syndromes

AU - Wiviott, Stephen D.

AU - Braunwald, Eugene

AU - McCabe, Carolyn H.

AU - Montalescot, Gilles

AU - Ruzyllo, Witold

AU - Gottlieb, Shmuel

AU - Neumann, Franz Joseph

AU - Ardissino, Diego

AU - De Servi, Stefano

AU - Murphy, Sabina A.

AU - Riesmeyer, Jeffrey

AU - Weerakkody, Govinda

AU - Gibson, C. Michael

AU - Antman, Elliott M.

PY - 2007/11/15

Y1 - 2007/11/15

N2 - BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P

AB - BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P

UR - http://www.scopus.com/inward/record.url?scp=36148983750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148983750&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0706482

DO - 10.1056/NEJMoa0706482

M3 - Article

C2 - 17982182

AN - SCOPUS:36148983750

VL - 357

SP - 2001

EP - 2015

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 20

ER -